Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression
Frontiers in Oncology · 04.03.2026 · 16
DOI: 10.3389/fonc.2026.1814738 ↗Kurz gefasst
Korrektur in der Zeitschrift Frontiers in Oncology, online erschienen am 04.03.2026. Verfasst von Yi Shi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
- Department of Pathology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China.
Zitieren
APA
Shi, Y., Chen, F., Weng, Y., Zeng, H., & Chen, G. (2026). Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1814738
Vancouver
Shi Y, Chen F, Weng Y, Zeng H, Chen G. Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1814738
BibTeX
@article{Shi2026,
author = {Shi, Yi and Chen, Fangfang and Weng, Yuanyuan and Zeng, Hang and Chen, Gang},
title = {Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1814738}
}
EUVIMED